March 14, 2017
Nativis Convenes Inaugural Ultra-Low Radio Frequency Energy Technology Advisory Board (TAB) Meeting
Nativis Inc., a clinical stage life science bio-electronic company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced the inaugural ultra-low Radio Frequency Energy (ulRFE™) Technology Advisory Board meeting held in Seattle.
“Nativis has the potential to transform the approach for treating cancer and other serious diseases using its proprietary ulRFE™ technology. To better understand and advance the technology, we convened several experts that will help us better understand the Mechanism of Action of each ulRFE product, as an important step in fully optimizing the delivery of ulRFE to patients,” stated Chris Rivera, CEO of Nativis.
Participants in the first ulRFE TAB meeting were Dr. Jack Tuszynski, Dr. Todd Mockler, Dr. Charles Cobbs, Dr. Dan Kisner, Dr. Gabriel Vogeli, Dr. Xavier Figueroa and Mike Butters, co-founder of Nativis.
“The objective of our TAB is to help Nativis better understand how our ulRFE technology can specifically and consistently produce safe biological effects similar to proven drugs and chemicals, as well as regulate metabolic pathways to patients with a challenging disease,” stated Mike Butters, co-founder and Director of Nativis. “This will help us to optimize ways to improve human health with this novel technology.”
“As a physicist and experimental oncologist, I am very intrigued and excited to be involved in Nativis’ TAB,” stated Dr. Jack Tuszynski, Allard Chair & Professor, Experimental Oncology, Department of Oncology at the University of Alberta Cross Cancer Institute. “I have been studying the electrostatic surface potential of molecules throughout my career and believe that Nativis has discovered how to harness this energy and reapply it to biological systems with great precision as if the chemistry were present. I am looking forward to studying this technology and helping the company better understand how it is working.”
“The results of Nativis’ pre-clinical and clinical trials have been profound. The opportunity for multi-disciplinary discussions with other TAB members will likely accelerate both our understanding of this most promising technology and the time it will take to bring this to market,” said Dr. Todd Mockler, Member and Principle Investigator, Donald Danforth Plant Science Center.
The Nativis TAB intends to meet regularly and expand its members based on additional expertise that will contribute to better understanding the potential for ulRFE technology.
About Nativis, Inc.
Founded in 2002 and headquartered in Seattle, WA, Nativis is a clinical-stage bio-electronics company. Nativis has invented and patented a groundbreaking technology that utilizes precisely targeted, ultra-low radio frequency energy (ulRFE) to specifically regulate metabolic pathways on the molecular and genetic levels – without chemicals, radiation or drugs – delivered via a simple-to-use, non-invasive device called Nativis Voyager®. The company’s goal is to transform disease treatment on a global scale with ulRFE that can potentially be applied to a wide range of conditions and other health-related needs (including agriculture, bio-fuels and veterinary medicine, to name a few). Nativis’ initial focus is on the treatment of patients with brain cancer (initially, recurrent glioblastoma), who are not well served by conventional standard of care therapies, which often result in poor outcomes and devastating side effects. Additional pre-clinical work is being completed for melanoma, lung cancer, liver cancer, inflammatory disease and chronic pain.
Investor Relations Contact:
Lee Roth / Tram Bui
firstname.lastname@example.org / email@example.com
646-536-7012 / 7035
Media Relations Contact:
Aaron Blank / Amber Benson